AKEBIA THERAPEUTICS, INC. (AKBA) Total liabilities 2016–2025
AKEBIA THERAPEUTICS, INC. (AKBA) total liabilities at each fiscal year-end, per SEC filings.
$344.0MFY2025 · since FY2016: $232.1M → $344.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $344.0M | +27.5% |
| FY2024 | $269.9M | -0.9% |
| FY2023 | $272.3M | -22.4% |
| FY2022 | $350.8M | -23.0% |
| FY2021 | $455.3M | +14.8% |
| FY2020 | $396.5M | +5.3% |
| FY2019 | $376.4M | +4.4% |
| FY2018 | $360.6M | +49.2% |
| FY2017 | $241.7M | +4.1% |
| FY2016 | $232.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AKBA financial trends
AKBA RevenueAKBA Net incomeAKBA Net marginAKBA Gross profitAKBA Gross marginAKBA Operating incomeAKBA Operating marginAKBA Operating cash flowAKBA Free cash flowAKBA Capital expendituresAKBA Return on equityAKBA Stock buybacksAKBA Dividends paidAKBA Total assetsAKBA Shareholders’ equityAKBA overview →